ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis — Active Not Recruiting • Phase III • Rheumatology • NCT06624228.
- Bimekizumab compared to risankizumab for treating active psoriatic arthritis over 16 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA). Conditions: Psoriatic Arthritis Interventions: Bimekizumab, Risankizumab, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 684 participants